Ptc Therapeutics, Inc. (PTCT) Institutional Ownership

Ownership Summary

Ptc Therapeutics, Inc. (NASDAQ:PTCT) currently has 6 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The percentage of Ptc Therapeutics owned by institutions changed from 94.5% in September 2025 to 1.1% in December 2025, marking a slight down trend.
• In percentage terms, this reflects as a holdings change of 279.31% quarter on quarter, and a decrease of 97.51% year over year.
• During the quarter, 3 institutions bought more Ptc Therapeutics shares, 1 sold shares, and 2 of the 6 total investors held their position steady.
• The total number of shares held by institutions in Ptc Therapeutics increased to 967.72K as of December 2025, a net change of up by 712.60K shares quarter on quarter, and down 76.57Mn shares year over year.
• As of December 31, 2025, SG Americas Securities, LLC held Ptc Therapeutics's largest shareholding position with over 894.46K shares, representing 1.02% of total outstanding shares.
• Among the most significant buyers of Ptc Therapeutics during December 2025 were SG Americas Securities, LLC (764.36K), GAMMA Investing LLC (893), Diversified Trust Co (817).
• Leading sellers of Ptc Therapeutics stock in December 2025 included Assenagon Asset Management S.A. (53.48K).
• The top 6 institutional holders of Ptc Therapeutics for the quarter ending December 2025 included SG Americas Securities, LLC (894.46K), Assenagon Asset Management S.A. (54.17K), Diversified Trust Co (17.39K), GAMMA Investing LLC (1.45K), True Wealth Design, LLC (229), Versant Capital Management, Inc (16).